CD8A and cancer: On the other hand, treatment of cancer patients with daily subcutaneous PEGylated IL-10 resulted in immune and CD8+ T cell activation and serum IL-10 levels of 18.9 ng/mL [26], which is very similar to the perfusate IL-10 levels in our high-dose MSCIL-10 group.